PCM
AMAG

Pentwater Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Pentwater Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-133,100
Closed -$1.54M – 191
2019
Q3 		$1.54M Buy
+133,100
New +$1.4M 0.02% 98

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Pentwater Capital Management's AMAG Position: Q4 2019 in Review

Pentwater Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q4 2019, closing a stake of 133,100 shares — an estimated $1.54M sold.

Pentwater Capital Management first reported a position in AMAG in Q3 2019 and held it in 1 quarter. The position peaked at $1.54M in Q3 2019. 134 funds tracked by Wall St. Rank hold AMAG as of Q4 2019.

  • Pentwater Capital Management reported no remaining AMAG Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Pentwater Capital Management sold 133,100 AMAG Pharmaceuticals shares in Q4 2019, an estimated $1.54M.
  • Pentwater Capital Management first reported a position in AMAG Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Pentwater Capital Management's AMAG Pharmaceuticals position peaked at $1.54M in Q3 2019.
  • 134 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2019.

Based on Pentwater Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.